SCHEMBL6174574

SCHEMBL6174574

COc1cccc(CCCC(=O)O)c1C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 1/20 0.50
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.47
ALOX5 P09917 1/20 0.45
PTGS2 P35354 1/20 0.45
LTB4R Q15722 2/20 0.45
LTB4R2 Q9NPC1 1/20 0.45
PTGER1 P34995 1/20 0.45
PTGER4 P35408 1/20 0.45
PTGER3 P43115 1/20 0.45
PTGER2 P43116 1/20 0.45
HDAC1 Q13547 2/20 0.45
HDAC6 Q9UBN7 2/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HDAC3 O15379 1/20 0.43
MAPK1 P28482 1/20 0.43
ADRA1A P35348 1/20 0.43
HDAC4 P56524 1/20 0.43
SLC6A3 Q01959 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3954801 0.90 LMNA (0.50) PPARALMNAPTGER1PTGER4PTGER3
SCHEMBL11708826 0.87 FFAR4 (0.44) LMNAHPGDHDAC1HDAC6MEN1
SCHEMBL3264881 0.85 HPGD (0.57) LMNAHPGDHDAC1HDAC6HDAC3
SCHEMBL612449 0.84 FFAR4 (0.51) PPARALMNAHPGDPTGER4PTGER3
SCHEMBL11846949 0.83 CYP2C9 (0.52) PPARALMNAHPGDMEN1KMT2A
SCHEMBL10836137 0.83 MTNR1A (0.56) LMNAHPGDLTB4RLTB4R2
SCHEMBL1206771 0.81 LTB4R (0.56) PPARALMNAHPGDLTB4RLTB4R2
SCHEMBL1454107 0.80 PTGER1 (0.49) PPARALTB4RLTB4R2PTGER1PTGER4
SCHEMBL6172042 0.80 ALOX5 (0.50) PPARALMNAHPGDALOX5PTGS2
SCHEMBL2310865 0.80 STING1 (0.54) PPARALMNAHPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114397384-A Method for detecting microcystin content in water by high-pressure liquid chromatography-mass spectrometry 江苏中宜金大分析检测有限公司 2022-04-26 CN disclosed
EP-0966446-B1 BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE WARNER LAMBERT CO (US) 2005-10-19 EP disclosed
US-6528535-B2 Anticancer agents; restenosis WARNER-LAMBERT COMPANY 2003-03-04 US disclosed
US-20020006936-A1 Bicyclic inhibitors of protein farnesyl transferase BIKKER JACK (US) 2002-01-17 US disclosed
US-6265422-B1 ANTICANCER AGENTS; CARDIOVASCULAR DISORDERS WARNER-LAMBERT COMPANY 2001-07-24 US disclosed
US-6133303-A VARIOUS INDENE DERIVATIVES, WITH THE EXCEPTION OF 5-(2-IMIDAZOLE-1-YL-ETHOXY)INDAN-1-ONE; TREATING CANCER AND TREATING OR PREVENTING RESTENOSIS OR ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 2000-10-17 US disclosed
EP-0966446-A1 BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE WARNER-LAMBERT COMPANY (US) 1999-12-29 EP disclosed
WO-1998034921-A1 BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE WARNER-LAMBERT COMPANY (US) 1998-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006936-A1 Bicyclic inhibitors of protein farnesyl transferase FNTA, FNTB, SREBF1 PPARA 3156/4885LMNA 2017/4885HPGD 1762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.